Post hoc analysis of a trial in 170 patients with relapsing ANCA-associated vasculitis re-induced with rituximab: musculoskeletal involvement (OR 2.8) was associated with relapse during maintenance, and CD19+ B cells (OR 2.5) and ANCA reappearance (OR 3.2) off treatment.
Secondary analysisn = 170
Romich et al. Risk Factors for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Among Patients With Relapse After Induction of Remission With Rituximab